

## Highly Specialised Technology Committee Interests Register

**Topic:** Exagamglogene autotemcel for treating sickle cell disease [ID4016]

**Publication Date:** 26 February 2025

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Emtiyaz Chowdhury	Committee Member	Direct – Non-financial professional	Emtiyaz’s employer is Parexel. Parexel provides services to Vertex. Emtiyaz has not been involved with any activities related to this technology in either indication.	23/01/2024 23/04/2024 10/10/2024	It was agreed that Emtiyaz’s declaration would not prevent him from participating in discussions on this appraisal.
Stuart Mealing	Committee Member	Direct – Non-financial professional	Stuart is currently leading the development of a global economic model for Spectra Optia, for Terumo BCT, that will be parameterised using data from four countries, one of which is in the UK. Spectra Optia is listed as a relevant technology, but Terumo are not listed as a stakeholder.	23/01/2024 10/10/2024	It was agreed that Stuart’s declaration would prevent him from participating in discussions on this appraisal.
Sarah Davis	Committee Member	Direct - Professional	Sarah is employed by the University of Sheffield. The University of Sheffield NICE Decision Support Unit produced a report for this appraisal.	14/02/2024 08/05/2024	It was agreed that Sarah’s declaration would not prevent her from participating in discussions on this appraisal.
Dr Emma Drasar	Clinical Expert	Direct – Financial and non-financial	Dr Drasar has provided consultancy and speaking services for GBT (now Pfizer), Vertex, NICE, and Novartis. Dr Drasar has also provided speaking and consultancy for UKTS.	05/07/2023 10/10/2024	It was agreed that Dr Drasar’s declaration would not prevent them from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Josh Wright	Clinical Expert	Direct – Financial	Dr Wright chaired a session for Vertex, but the topic was not related to this appraisal.	08/05/2024 10/10/2024	It was agreed that Dr Wright's declaration would not prevent them from providing expert advice to the committee.
Dr Ben Carpenter	Clinical Expert	Direct - Financial	<ul style="list-style-type: none"> <li>Dr Carpenter has been a Vertex meeting speaker in July 2023, September 23, and March 2024. He participated in a Vertex Ad board in December 2021.</li> <li>Dr Carpenter is the Principal Investigator for studies 111 and 131 in the ongoing CRISPR study</li> <li>Dr Carpenter is potentially part of the unit (University College London Hospitals Foundation) delivering such therapies.</li> </ul>	05/04/2024 10/10/2024	It was agreed that Dr Carpenter's declaration would not prevent them from providing expert advice to the committee.
Jasdeep Hayre	NICE Associate Director	Direct – Financial	Jasdeep accepted a role at GSK but is not starting employment until 30 September 2024. GSK is not a current comparator company. GSK has a Phase I trial underway for sickle cell disease. This technology is currently not in the NICE process, and at best, several years away for the market.	18/07/2024	It was agreed by the Programme Director, that this would not prevent Jasdeep from further work on this topic, given the early stage of this product, and because it is not a comparator, or likely imminent comparator at this time.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Harveen Ubhi	Patient Expert	Non-financial professional	<p>Harveen declared an organisation interests (Anthony Nolan):</p> <ul style="list-style-type: none"> <li>Anthony Nolan has published positions on sickle cell and the need for new treatments on our social media in the last 12 months.</li> </ul>	10/10/2024	It was agreed that Harveen's declaration would not prevent them from providing expert advice to the committee.